Drug intelligence / Profile preview

dihydroxyaluminum sodium carbonate

Development stage: Unknown
Lead developer: Anmol Chemicals
Modality: Small Molecules
Administration: Oral

Overview

Dihydroxyaluminum sodium carbonate is a basic inorganic salt and antacid used to treat heartburn and related symptoms. It acts by neutralizing hydrochloric acid in gastric secretions, forming aluminum chloride and water. This process increases gastric pH, inhibits pepsin activity via pH elevation and adsorption, and may provide cytoprotective effects through increased bicarbonate ion concentration and prostaglandin production. It is a component of several over-the-counter antacid products such as Rolaids[1][2][3][8].

Brand names: RolaidsKompensan-S Forte
Other names: carbaldrate anhydrousaluminum sodium dihydroxide monocarbonatedihydroxo-aluminium-natrium-carbonatsodium (carbonato)dihydroxyaluminate(1-)

Targets

PEP (Pepsin)

Beyond the preview

Go deeper on dihydroxyaluminum sodium carbonate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dihydroxyaluminum sodium carbonate.

Explore the full profile